Introduction {#sec0005}
============

Integrins are heterodimeric cell surface proteins that facilitate signalling between the intracellular and extracellular environments. Each integrin consists of one α and one β subunit. Together, they are capable of forming 24 unique integrins in humans (reviewed by [@bib0125]). αvβ6 is expressed exclusively on epithelial cells but is absent or expressed at low levels in normal healthy adult tissue ([@bib0055]). In contrast, αvβ6 expression is increased during development ([@bib0050]), wound healing ([@bib0105]), cancer (reviewed by Bandyopadhyay and Raghavan, 2009) and fibrosis ([@bib0185]), all of which are processes requiring tissue remodelling ([Fig. 1](#fig0005){ref-type="fig"}).Fig. 1ITGB6 RNA expression in human normal tissue plotted as rates per kilobase million (RPKM). Data were obtained from Human Protein Atlas Dataset available from proteinatlas.org.\<<https://www.proteinatlas.org/ENSG00000115221-ITGB6/tissue#gene_information>\>Fig. 1

αvβ6 binds to proteins containing the RGD (Arg-Gly-Asp) motif ([@bib0060]). Well characterised αvβ6 ligands include fibronectin ([@bib0060]) and the Transforming Growth Factor Beta (TGF-β) pro-peptide, Latency Associated Peptide (LAP) ([@bib0185]; [@bib0015]). LAP is post-translationally cleaved from TGF-β1 but remains directly associated with the cytokine, anchored as a homodimer to the extracellular matrix (ECM) via latent TGFβ binding protein 1 ([@bib0020]). This whole complex remains inert and is referred to as latent TGF-β1. Binding of αvβ6 to LAP physically moves LAP and exposes TGF-β1 to its receptors on adjacent cells, permitting an acto-myosin dependent activation of TGF-β1 ([@bib0185], [@bib0020]). Binding domains are also present on the cytoplasmic tail of integrin β6, which recruits signalling and structural partners including HAX-1, Fyn, ERK2, and Kindlin-1 ([@bib0010]; [@bib0145]; [@bib0205]; [@bib0180]). Extracellular ligand binding to αvβ6 is able to effect a conformational change in the cytoplasmic tail and thus initiate downstream signalling (outside-in signalling), while cytoplasmic tail binding may also affect extracellular ligand binding (inside-out signalling).

Through these and other signalling pathways, αvβ6 regulates many basic functions of the cell, such as proliferation ([@bib0005]), migration ([@bib0115]), and ECM degradation ([@bib0265]; Morgan et al., 2004). Expression of αvβ6 is found in up to one third of all solid tumours ([@bib0215]) and is associated with a poorer prognosis and increased invasiveness ([@bib0190]). αvβ6 expression is also associated with the progression of pulmonary fibrosis through its activation of TGF-β1 ([@bib0090]).

The β6 subunit was first isolated from guinea pig epithelial cells in 1990 ([@bib0235]). At this time, only three β subunit structures had been identified in mammalian cells, with emerging evidence for several other subunits ([@bib0065]). Sheppard and colleagues, observing that β1, β2 and β3 had large consensus regions in their sequences, designed primers against these conserved regions and successfully amplified β6. Further screening in human cell lines led to the identification of the β6 nucleotide sequence from the pancreatic cell line FG-2. It was later determined that *ITGB6* was located on chromosome 2 ([@bib0135]), specifically 2q24.2 ([@bib0085]).

Transcriptional regulation {#sec0010}
==========================

As the exclusive binding partner of αv, β6 availability determines the cellular expression of αvβ6. Breakthrough work characterising the structure and transcriptional regulation of ITGB6 was performed by [@bib0285]. They identified both the transcriptional start site (TSS), 204 bp upstream of the translation initiation site, and the core promoter of ITGB6 using oral squamous cell carcinoma cells (OSCCs). A functional TATA box was located -24bp to -18bp upstream of the TSS, and binding sites for transcription factors C/EBPα (CCAAT-enhancer-binding protein α) and signal transducer and activator transcription 3 (STAT3) between -289bp and -150bp. Further binding sequences for Ets-1 and Smad proteins were also identified, however the basal rate of ITGB6 expression in OSCC cells was primarily defined by STAT3 and C/EBPα binding ([@bib0285]).

This was not the first time STAT3 had been implicated in the possible regulation of *ITGB6*. Previous work showed that constitutive STAT3 activation led to an increase in cell migration and motility in prostate cancer cell lines ([@bib0030]). This was attributed to an increase in *ITGB6* mRNA expression within 4 hours of STAT3 simulation, whereas inhibition of STAT3 by shRNA resulted in downregulation of *ITGB6* mRNA.

Work performed in colon carcinoma cell lines by Bates and colleagues in 2005 also revealed a binding domain for Ets-1 in the *ITGB6* promoter region. As an initiating factor of the epithelial-mesenchymal transition (EMT), it was hypothesised that Ets-1 could possibly play a role in *ITGB6* expression. They demonstrated that Ets-1 was able to bind to the *ITGB6* promoter region and transactivate the promoter, resulting in increased *ITGB6* transcription ([@bib0035]).

In 1992, it was discovered that TGF-β1 works as part of a positive feedback loop promoting expression of αvβ6 ([@bib0230]). In an effort to determine the mechanisms by which TGF-β1 regulates *ITGB6* expression using a pulmonary fibrosis model, Tatler and colleagues identified the location of a suppressor region in the *ITGB6* gene ([@bib0255],[@bib0260]). They found that deletion of the region -818bp to -738bp leads to a significant increase in *ITGB6* expression. This confirmed work by Xu and colleagues, who also showed that deletion from -909bp to -421bp leads to maximum transcriptional activity ([@bib0285]).

Another transcription factor of the Ets family was also shown to have a role in regulating *ITGB6* ([@bib0255],[@bib0260]). Following *in silico* analysis, it was found that the ETS domain-containing protein Elk1 was able to bind to a site in the apparent suppressor region and reduce *ITGB6* expression. Loss of Elk1 *in vivo* led to an increased basal expression *ITGB6* mRNA ([@bib0255],[@bib0260]).

Smad transcription factors mediate classical TGF-β1 signalling ([@bib0075]). Disruption of a Smad binding site within the same suppressor region of *ITGB6* (-818bp to -738bp) led to abrogation of *ITGB6* transcription induced by TGF-β1 ([@bib0255],[@bib0260]). Inhibition of Smad3 led to a decrease in *ITGB6* transcription and, moreover, Smad3^-/-^ mice treated with TGF-β1 had reduced expression of αvβ6. TGF-β1-induced *ITGB6* expression regulated by Smad proteins has been extensively documented, including in bile duct epithelial cells (BDECs) where Smad3 inhibition reduced TGF-β1 induced *ITGB6* mRNA ([@bib0270]; [@bib0220]). Conversely, [@bib0285] concluded that Smad binding domain activity was not essential for basal expression in OSCCs.

Regulation of *ITGB6* by TGF-β1 was further explored by Xu and colleagues (2017). They identified that the AP1 subunit JunB binds directly to the *ITBG6* promoter region. Furthermore, they identified a role for histone H3 and H4 acetylation following treatment with TGF-β. Inhibition of Histone Deacetylase (HDAC) resulted in increased acetylation of H3 and H4, leading to an increased expression of ITGB6. Histone acetylation was initiated by recruitment of the cAMP response element binding protein (CBP), which acts as both a histone acetyltransferase (HAT) and a scaffold that promotes the recruitment of further components required for gene transcription ([@bib0130]).

Given that transcription of *ITGB6* is almost certainly a mechanism determining its availability at the cell surface, understanding its regulation could identify potential therapeutic targets in diseases where αvβ6 is overexpressed. Although recent work has greatly improved our understanding of the structure of the promoter region, and binding sites of transcription factors, extensive work still remains to fully characterise how these transcription factors regulate *ITGB6* transcription ([Fig. 2](#fig0010){ref-type="fig"}).Fig. 2*ITGB6* Gene Promoter Region Structure. *ITGB6* contains a TATA box -18 bp upstream of the TSS (Transcriptional Start Site). An area found to promote ITGB6 transcription is located at -289bp to 150 bp, including binding domains for C/EBPα (CCAAT-enhancer-binding protein α), AP-1 (Activator Protein 1) and STAT3 (Signal transducer and activator of transcription 3). A suppressor region can be found -738bp to -818bp with a binding region for Elk1 ETS Like-1 protein). Smad3 (Smad Family Member 3) binding domain is also found in this region, but results in ITGB6 promotion. Translation Initiation Site (TIS) is found +204 bp downstream of the TSS. ([@bib0285]; [@bib0255],[@bib0260].Fig. 2

Post-Transcriptional Regulation {#sec0015}
===============================

Following gene transcription, protein expression may also be regulated by multiple post-transcriptional processes. One of the most significant points of post-transcriptional regulation happens at the initiation of mRNA translation. Eukaryotic translation initiation factor 4 (eIF4E) binds to the 5' end of mRNA, initiating protein translation ([@bib0210]). eIF4E is known to selectively increase the expression of proteins with 'weak' mRNA ([@bib0095]). This refers to proteins with a long and/or complex 5' UTR (untranslated region), usually proteins expressed at low levels in healthy tissue, as opposed to 'strong' mRNAs, which have a short and simple 5'UTR and are usually housekeeping genes. eIF4E expression is known to be dysregulated in malignancy (, [@bib0245]). De [@bib0040] reviewed the effect of eIF4E in malignancy, describing its ability to selectively upregulate translation of some pro-tumorigenic proteins (e.g. Vascular Endothelial Growth Factor (VEGF)), which tend to have a more complex 5'UTR and require eIF4E for translation.

*ITGB6* mRNA has a long 5'-UTR and is GC rich, both of which are characteristics of 'weak' mRNA. Combined expression of eIF4E and *ITGB6* can predict a poorer prognosis in colon cancer ([@bib0195]). Furthermore, siRNA-induced depletion of eIF4E significantly reduced protein expression of β6 ([@bib0080]). Further investigation in to eIF4E and αvβ6 expression in other models has yet to be performed. Thus, while we now know a significant number of the transcriptional regulators of ITGB6, we have not yet linked these data to how ITGB6 is upregulated in disease, especially cancer.

Mouse Models {#sec0020}
============

*Itgb6* knockout mice have been used to study the downstream effects of αvβ6 and improve our understanding of its biology. The first characterisation of *Itgb6* deficient mice was published in 1996, with surprising results ([@bib0120]). Given the role αvβ6 plays in wound healing in human tissue ([@bib0105]), it was hypothesised that *Itgb6* knockout mice would exhibit wound healing abnormalities. The authors also postulated that *Itgb6* knockout mice would display developmental abnormalities due to the involvement of αvβ6 in cell migration and proliferation ([@bib0005]; [@bib0115]). However, the *Itgb6* knockout mice developed normally, with no difference in their wound healing ability. Rather, they exhibited moderate but significant inflammation in the lungs and skin. In the same study, *Itgb6* knockout mice did not develop fibrosis in response to bleomycin. This phenotype is remarkably similar to TGF-β1 deficient mice, and is attributable to TGF-β1 activation by αvβ6 ([@bib0185]). Interestingly, inflammation was only observed in the skin and airways of *Itgb6* knockout mice, despite the potential for expression of αvβ6 in other epithelial tissues. The authors offered this was perhaps due to the housing conditions of the mice causing irritation in the skin and lungs. Neonatal *Itgb6* knockout mice also developed a temporary baldness. Whether this was due to the subsequent discovery that αvβ6 plays a role in hair follicle regeneration remains to be determined ([@bib0280]).

The fibrosis phenotype of *Itgb6* knockout mice was further explored in *Itgb6*/Thrombospondin 1 (*Tsp-1*) double-null mice ([@bib0150]). Thrombospondin-1 also activates latent-TGF-β1 ([@bib0070]) and in the double knockout model there was a higher incidence of inflammation and pneumonia, which more closely resembles the phenotype of TGF-β1 null mice ([@bib0240]). Whilst no significant differences in tumour incidence were observed between the *Itgb6*^-/-^ and the *Itgb6*^-/^; *Tsp-1^-/-^* mice, the authors found that *Itgb6*^-/-^ mice developed both benign and malignant tumours at a significantly higher rate than the *Tsp*^-/-^ mice.

Another characteristic of *Itgb6*^-/-^ mice is their eventual development of emphysema ([@bib0175]). In the alveolar macrophages of *Itgb6*^-/-^ mice, MMP12, an enzyme strongly associated with the pathogenesis of emphysema, is expressed 200-fold higher than in wild-type counterparts ([@bib0110]). Although at birth the size of the alveoli is normal, by six months of age the alveolae of *Itgb6*^-/-^ mice are significantly larger and exhibit mild emphysema, which increases in severity with age ([@bib0110]).

Mice deficient in *Itgb6* develop chronic periodontal disease (periodontitis) (Ghannad et al., 2008), an advanced stage of gingivitis in which the gums pull away from the teeth, leaving space or 'pockets' between the teeth and gums that become infected. The consequent immune response leads to degradation of the connective tissue between the teeth and gums. An important interface in the development of periodontal disease is the junctional epithelium (JE), which expresses αvβ6 and is involved in adhesion of the gingiva to the teeth. By 12 months of age, *Itgb6*^-/-^ mice develop abnormal JE, exhibit periodontal pockets and show evidence of inflammation and bone degradation (Ghannad et al., 2006; [@bib0045]).

*Itgb6*^-/-^ mice also develop amelogenesis imperfecta, a disorder affecting the development of teeth ([@bib0170]). Amelogenesis imperfecta causes a range of symptoms, including abnormally small teeth prone to breakage and discolouration. Cases of amelogenesis imperfecta have also been observed in clinical studies in patients with *ITGB6* mutations ([@bib0275]; [@bib0200]).

Clinical Cases of *ITGB6* mutations {#sec0025}
-----------------------------------

The first clinical case associated with an *ITGB6* mutation was documented in 2013, in which a 7-year-old girl presented with enamel malformations but was otherwise asymptomatic ([@bib0275]). Following whole genome sequencing, it was revealed that she had inherited 2 distinct missense mutations in *ITGB6*. As part of the same study, a second child displaying symptoms of amelogenesis imperfecta was examined and he too had a bi-allelic *ITGB6* mutation. Polymorphism Phenotyping (Polyphen) analysis indicated that both mutations were of high probability of affecting β6 protein structure and causing disease. These and other cases of *ITGB6* mutations have been documented across a number of conditions ([Table 1](#tbl0005){ref-type="table"}).Table 1Summary of reported clinical cases where ITBG6 is mutated or deleted.Table 1PatientMutationLocationProtein ChangeClinical PresentationPublication7 year old female2 distinct missense mutations: c.427 G \> A c.825 T \> AExon 4 Exon 6A143T H275QAmelogenesis Imperfecta[@bib0275]8 year old malec.1846C \> TExon 11R616XAmelogenesis Imperfecta[@bib0275]3 sisters; aged 7,9 and unknownc.586C \> AExon 4P196TAmelogenesis Imperfecta[@bib0200]Newborn female (15 min)Deletion2q22q31n/aMultiple congenital abnormalities. Deceased.[@bib0165]20 year old femaleDeletion2q23q31n/aCognitive deficit and dysmorphic features. Deceased.[@bib0225]2 year old maleDeletion2q23q24.3n/aDysmorphic features, congenital heart defects. Deceased.[@bib0155],[@bib0160]3 year old femaleDeletion2q24.1q31.1n/aDysmorphic features, developmental delay and seizures. Deceased.[@bib0140]9 year old maleDeletion2q23q31n/aCognitive deficit, seizures[@bib0100]2 month old femaleDeletion2q24.2q24.3n/aSevere pulmonary emphysema, seizures, delayed growth and dysmorphic features[@bib0250]3 siblings; Male aged 40; Females aged 39 and 33c.898 G \> AExon 3E300KAlopecia and Cognitive deficit, Amelogenesis ImperfectaAnsar et al. 2015

These cases were the first reported examples of mutations in the *ITGB6* gene causing amelogenesis imperfecta. Interestingly, they reported no other clinical symptoms, such as pulmonary inflammation as reported in mouse models. However, it is unknown whether the authors performed a detailed clinical examination of the children. Similarly, further reported cases of amelogenesis imperfecta with *ITGB6* mutations failed to disclose other possible clinical symptoms, or whether these were investigated ([@bib0200]).

There is a collection of clinical cases where a large deletion in the 2q24 region encompassing the *ITGB6* gene has resulted in respiratory complications in the patient ([@bib0250]). These authors described a case of a 2-month-old girl who, among other symptoms, developed severe pulmonary emphysema. After confirming *ITGB6* was deleted, they hypothesised that there was a relationship between this deletion and the respiratory complications experienced by the child. However, it is estimated that a total of 34 genes were affected by this deletion. Thus, her emphysema may not have been caused by the *ITGB6* deletion alone, despite the similarities in phenotype with the *Itgb6*^-/-^ mice. A further three cases ([@bib0225]; Moller et al., 1984 and [@bib0140]) document patients with large deletions in the 2q24 region that included *ITGB6*, two of which resulted in fatalities caused by respiratory complications.

A novel homozygous missense mutation in *ITGB6* was found in three members of a Pakistani family presenting with alopecia, intellectual disabilities, and symptoms consistent with amelogenesis imperfecta ([@bib0025]). It is perhaps worth noting that cognitive disabilities have not been noted in experimental mouse studies of *Itgb6*. The mutation was found in a highly conserved region of *ITGB6* which was predicted by *in silico* analysis to cause significant change to β6, which may its function. Thus, humans with loss of function *ITGB6* mutations exhibit some of the phenotypes observed in *Itgb6^-/-^* mice (alopecia, amelogenesis imperfecta, periodontitis, and emphysema) but this seems to vary between individuals, presumably due to the clinical severity of the different mutations. Further clinical exploration will result in a clearer picture of how specific mutations manifest.

Conclusions {#sec0030}
===========

Although a substantial amount of work has been performed to determine the structure of the *ITGB6* gene, there are many unanswered questions as to how β6 protein expression is regulated. Of note, limited work has been performed to further our understanding of post-transcriptional regulation of *ITGB6*, which likely plays a significant role in αvβ6 expression and biology. Furthermore, investigations of clinical cases involving *ITGB6* mutations have not been comprehensive and it is possible we have missed some understanding of the human phenotype that would help us fully appreciate the role of *ITGB6* in humans.
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